(NYSE:TGX) expects to release fourth quarter 2012 financial results before the market opens on February 14, 2013. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.
To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenics’ website,
. A replay will be available on the website for one month. A phone replay will be available until Midnight, February 21, 2013 by dialing 877-660-6853 or 201-612-7415, and entering the conference ID 408014.
Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business (
) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures, markets and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. The Company’s brachytherapy product line includes its palladium-103 TheraSeed
device and its iodine-125 AgX100™ device (